ArticleClinical case reports2025
Hemiplegic Migraine in a Patient With Neurologic Symptoms After Regadenoson Administration.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hemiplegic Migraine in a Patient With Neurologic Symptoms After Regadenoson Administration.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regadenoson, a selective adenosine A2A receptor agonist, is widely used as a stress agent for myocardial perfusion imaging. A2A receptor activation has been implicated in migraines due to its pro-nociceptive effects within trigeminal pain pathways. This case report discusses a 67-year-old female with headache, sudden onset unilateral weakness, and paresthesias after undergoing a PET-CT for ischemic evaluation. Subsequent lab and imaging studies were unconcerning for acute stroke or seizure, raising suspicion for hemiplegic migraine given her extensive neurologic history and rapid onset of symptoms. Regadenoson may be associated with hemodynamic instability and lowering of the seizure threshold. Patients should be screened for neurologic risk factors prior to receiving regadenoson to determine if alternate modalities for ischemic evaluation are more suitable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.